GGrantIndex
Sort

51,593 grants matching hepatitis

Antiviral agents directed to novel targets in the adenovirus proteinase

$781,650
Walter F. Mangel · Brookhaven Science Assoc-Brookhaven Lab · R01 · FY2011 · AI

NIDA Clinical Trials Network: Big South/West Node

$781,644
Madhukar H Trivedi · Ut Southwestern Medical Center · UG1 · FY2022 · DA

Immune response to COVID-19 vaccine in HIV infected men and women

$781,490
Charles R Rinaldo · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AI

Novel IL-23 inhibitor for the treatment of alcohol associated liver disease

$781,354
Rohit Loomba · University Of California, San Diego · U01 · FY2021 · AA

Studies of Atomic Bomb Survivors

$781,251
Kiyohiko Mabuchi · Division Of Cancer Epidemiology And Genetics · ZIA · FY2013 · CA

Spectinomycin analogs for NTM infections

$781,206
Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2024 · AI

Identification and validation of targets for therapeutic intervention in rare diseases of intermediary metabolism

$781,186
Brian Robert Wamhoff · Hemoshear Therapeutics, Llc · R44 · FY2017 · TR

Deciphering the role of ddhCTP in viperin-related functions

$781,139
Tyler L Grove · Albert Einstein College Of Medicine · R01 · FY2024 · AI

Bupropion for smoking cessation during pregnancy

$781,117
Gary D Hankins · University Of Texas Med Br Galveston · R01 · FY2013 · DA

Mechanisms of repeated control of acute hepatitis C infection in humans

$781,044
Andrea L Cox · Johns Hopkins University · U19 · FY2020 · AI

Therapeutic Strategies and Molecular Correlates in Aggressive B-cell Lymphomas

$780,978
Wyndham H Wilson · Division Of Clinical Sciences - Nci · ZIA · FY2024 · CA

Animal Model to study heterogeneous outcomes of HCV Infection and Pathogenesis

$780,961
Amit Kapoor · Research Inst Nationwide Children'S Hosp · R01 · FY2025 · AI

Monkey Alcohol Tissue Research Resource (MATRR)

$780,903
Kathleen A Grant · Oregon Health & Science University · R24 · FY2012 · AA

Breaching the species barrier: Towards an immunocompetent HBV-susceptible mouse model

$780,790
Charles M. Rice · Rockefeller University · R01 · FY2025 · AI

Molecular and structural characterization of broadly neutralizing anti-HCV antibodies

$780,775
Justin Richard Bailey · Johns Hopkins University · R01 · FY2025 · AI

Development and Validation of Novel NSG Mouse Models for Human Stem Cell Therapy

$780,422
Dale L Greiner · Univ Of Massachusetts Med Sch Worcester · R24 · FY2014 · OD

Human Genetic determinants of HBV recovery

$780,411
David L Thomas · Johns Hopkins University · R01 · FY2024 · AI

Sphingosine kinase 2 in sexual dimorphism of hepatocellular carcinoma

$780,346
Christopher D Green · Virginia Commonwealth University · R01 · FY2025 · CA

YAP signaling in the pathogenesis of NAFLD in people living with HIV

$780,234
Raymond T Chung · Massachusetts General Hospital · R01 · FY2024 · DK

Research to Improve and Standardize Marmoset Nutrition and Dietary Husbandry

$780,224
Suzette D Tardif · Texas Biomedical Research Institute · R24 · FY2017 · OD

Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation

$780,148
Siu Kit Lam · Immunophotonics, Inc. · R44 · FY2024 · CA

Understanding the Regional Ecology of a Future HIV Vaccine

$780,044
Dolores Albarracin · University Of Pennsylvania · R01 · FY2023 · MH

TION OF CHOLECYSTOKININ-B RECEPTOR-POSITIVE STEM CELLS INDUCES HEPATIC CARCINOGENESIS

$780,000
Georgetown University · · FY2021 · Defense Health Agency

Integrated heart-liver-vascular systems for drug testing in human health and dise

$779,987
Gordana Vunjak-Novakovic · Columbia Univ New York Morningside · UH2 · FY2012 · EB

The Epidemiology of the Weiss Cohort Project

$779,861
Stanley H Weiss · Rbhs-New Jersey Medical School · R01 · FY2020 · DA